$BioNTech(BNTX)$ 现金和现金等价物：2022年1月6号约64亿欧元，加上辉瑞还欠77亿欧元应付款，现金等价物约141亿欧元（折合152亿美元）。Cash, Cash Deposits and Trade Receivables: As of December 31,
2021, cash and cash equivalents were €1,692.7 million and cash deposits,
which were returned to cash in January and February 2022, were
€375.2 million. In addition, trade receivables remained outstanding as
of December 31, 2021 mainly due to the contractual settlement of the
gross profit share under the COVID-19 collaboration with Pfizer, which
has a temporal offset of more than one calendar quarter. As Pfizer’s
fiscal quarter for subsidiaries outside the United States differs from
BioNTech’s financial reporting cycle, it creates an additional time lag
between the recognition of revenues and the payment receipt. Trade
receivables for example include the gross profit share for the third
quarter of 2021 (as defined by the contract) for which the settlement
payment was received subsequent to the end of the reporting period in
January 2022. Of the total trade receivables of €12,381.7 million which
were outstanding as of December 31, 2021, €4,693.6 million were received
in cash by January 16, 2022.